ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
公司代碼ADMA
公司名稱ADMA Biologics Inc
上市日期Oct 17, 2013
CEOGrossman (Adam S)
員工數量677
證券類型Ordinary Share
年結日Oct 17
公司地址465 State Route 17
城市RAMSEY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編07446
電話12014785552
網址https://www.admabiologics.com/
公司代碼ADMA
上市日期Oct 17, 2013
CEOGrossman (Adam S)